IBC Life Sciences Presents the 5th Annual International Antibody Therapeutics Conference
Posted on: Thursday, 27 September 2007, 15:00 CDT
IBC Life Sciences is pleased to announce that the 5th Annual International Antibody Therapeutics conference will return to San Diego, California on December 4-6, 2007. This meeting is held in parallel with the 18th Annual International Antibody Engineering meeting (December 2-6, 2007). Together the meetings will attract more than 700 delegates from around the world.
The 5th Annual International Antibody Therapeutics conference presents a focused look at the preclinical and clinical development of antibody-based drug products, with a program featuring twenty new case studies of antibody products now in development:
-- Clinical Updates of Cancer Therapeutics from Agensys, Amgen, Human Genome Sciences, Medarex and Seattle Genetics -- Clinical-Stage Advances from Abbott Laboratories, Genmab, KaloBios and Rinat Laboratories -- Preclinical Programs from Affitech, Armagen, Biogen Idec, Centocor, Micromet, Peregrine Pharmaceuticals and Wyeth -- Exciting Progress in Antibody Conjugates from Cambridge Antibody Technology, Immunogen, Medarex, MedImmune and Target-In
This annual conference provides a platform for clinical updates of therapeutic programs in cancer and other indications, and solutions to problems associated with immunogenicity, glycosylation and effector functions. Plus, attendees will be updated on the current status of the antibody therapeutics market, examine the current intellectual property environment and learn how antibody conjugation is improving the targeting for small and large molecule therapeutics.
Complete details on this meeting can be found at http://www.IBCLifeSciences.com/d4173 or to receive a press pass or arrange an interview with a speaker, email Dawn O'Connor at doconnor@ibcusa.com.
About IBC Life Sciences
IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life sciences industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. No other organization can make claim to the breadth and quality that IBC Life Sciences delivers in each meeting, giving the company recognition around the globe for quality, service and value. For more information, visit: http://www.IBCLifeSciences.com.
Contact: Dawn O'Connor IBC Life Sciences 508-614-1679 Email Contact
SOURCE: IBC Life Sciences
Source: MARKET WIRE
Related Articles
- Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
- IBC Life Sciences Presents the 19th Annual International Antibody Engineering Conference
- IBC Life Sciences Kicks Off the Annual BioProcess International(TM) Conference &Amp; Exhibition in Anaheim, California
- IBC Life Sciences Announces Keynote Schedule for Next Generation Vaccines Conference
- BioDelivery Sciences and Meda to Expand Clinical Development Program for BEMA(TM) Fentanyl
- IBC Life Sciences Presents the Annual Forum for the Antibody Engineering Community
- IBC Life Sciences Develops an Antibody Therapeutics Summit Based on New Industry Survey Results
- Human Genome Sciences Announces Phase 3 Clinical Development Program for Albuferon(TM) in Chronic Hepatitis C
- Human Genome Sciences Announces Phase 3 Clinical Development Program for LymphoStat-B(TM) in Systemic Lupus Erythematosus
User Comments (0)

RSS Feeds